RenovoRx RNXT

NASDAQ RNXT

$1.89 -0.11 (-5.29%)

As of: Sep 10, 2026 · 9:52 AM EDT

Key Stats

Market Cap91.29 Mn

P/E-6.91

P/S46.20

Div. Yield0.00

Add ratio to table…

About

RenovoRx is a life sciences company focused on developing targeted oncology therapies and commercializing the RenovoCath device, a U. S. Food and Drug Administration cleared local drug delivery system. The company’s proprietary Trans Arterial Micro Perfusion (TAMP) therapy platform uses RenovoCath to deliver chemotherapeutic agents directly to tumors via intra arterial infusion, aiming to increase drug concentration at the tumor site while reducing systemic exposure. RenovoRx is also advancing its drug device combination candidate, intra arterial gemcitabine delivered via RenovoCath (IAG), which is being evaluated in a Phase III trial for locally advanced pancreatic cancer.

Revenue is currently generated from the sale of RenovoCath devices to cancer centers and hospitals in the United States. In the year ended December 31, 2025, the company recorded approximately $1.1 million in revenue from RenovoCath sales, driven by repeat orders from existing customers and new placements at additional institutions. RenovoRx markets the device for its cleared indications, which include temporary vessel occlusion during arteriography, preoperative procedures, and chemotherapeutic drug infusion. The company anticipates further revenue growth as it expands its commercial footprint and continues to build its sales and marketing infrastructure.

RenovoRx operates in the competitive field of oncology drug delivery, where it faces competition from large pharmaceutical companies, specialized biotechnology firms, and established medical device manufacturers. Despite this, the company believes it holds advantages through its patented TAMP technology, which is supported by nine issued U. S. patents and additional international filings, and through the orphan drug designation granted to IAG for pancreatic and bile duct cancers, providing potential seven year market exclusivity upon approval. The presence of an existing reimbursement code for pressure mediated delivery catheters from the Centers for Medicare and Medicaid Services also creates a financial incentive for hospitals to adopt the technology.

The company’s customers are primarily U. S. cancer centers, hospitals, and healthcare institutions that use the RenovoCath device for its cleared indications. As of the February 2026 update, twelve centers were actively using the device, twenty one additional centers were evaluating or preparing for adoption, and a total of thirty three facilities had requested access to the technology. RenovoRx also notes that several of its customers are high volume National Cancer Institute designated centers, reflecting strong interest from leading oncology providers.

Investment Thesis

▲ Bull case

RenovoRx is demonstrating a validated and scalable commercial model where revenue growth is directly tied to the expansion of active commercial cancer centers using the RenovoCath device, with Q1 2026 revenue of $563 thousand representing 136% quarter-over-quarter growth and accounting for 51% of total 2025 revenue, indicating that the company has moved beyond strategy formulation into execution with tangible, repeatable results. The company’s ability to double its active center count from 8 at the end of 2025 to 16 by May 2026, coupled with a pipeline of 32 additional centers in evaluation, provides a clear runway to exceed its 2026 revenue guidance of $3 million to $4 million, as each new center contributes to recurring TAMP procedures driven by physician satisfaction and repeat ordering behavior, which management highlighted as a critical indicator of durable adoption. Furthermore, the transition of up to 15 active TIGER-PACT phase 3 trial sites to commercial use represents a near-term, underappreciated catalyst that could accelerate revenue growth in the second half of 2026, as these sites already have familiarity with the device and are motivated by observed clinical benefits, reducing the typical sales cycle and activation lag seen in new center onboarding.
The RenovoCath device benefits from exceptionally high gross margins of 85.1% in Q1 2026, reflecting a capital-efficient business model where the single-use nature of the catheter drives recurring revenue with minimal incremental cost per procedure, and management emphasized that ongoing R&D optimizations are focused on manufacturing streamlining rather than fundamental design changes, meaning that as procedure volumes increase with center expansion, operating leverage will significantly improve cash burn and accelerate the path to profitability without requiring substantial new investment. This structural advantage is reinforced by the company’s $12.4 million cash position as of March 31, 2026, which provides sufficient runway to fund operations into 2027, allowing management to focus purely on revenue generation and commercial scaling rather than fundraising distractions, a rare position for a early-stage medical device company in the interventional oncology space.
Physician advocacy and satisfaction are emerging as powerful, organic drivers of adoption, with clinicians citing the toxicity profile, potential lifespan preservation, and early efficacy signals as key reasons for preferring RenovoCath over systemic chemotherapy, particularly in locally advanced pancreatic cancer, and this real-world validation is being amplified by investigator-initiated trials (IITs) in metastatic and resectable pancreatic cancer at institutions like Moffitt Cancer Center and the University of Vermont, which, while not yet commercialized, are building clinical evidence that could expand the addressable market beyond the current TIGER-PACT indication and create additional demand channels that management did not fully quantify but acknowledged as areas of strong interest.

RenovoRx is demonstrating a validated and scalable commercial model where revenue growth is directly tied to the expansion of active commercial cancer centers using the RenovoCath device, with Q1 2026 revenue of $563 thousand representing 136% quarter-over-quarter growth and accounting for 51% of total 2025 revenue, indicating that the company has moved beyond strategy formulation into execution with tangible, repeatable results. The company’s ability to double its active center count from 8 at the end of 2025 to 16 by May 2026, coupled with a pipeline of 32 additional centers in evaluation, provides a clear runway to exceed its 2026 revenue guidance of $3 million to $4 million, as each new center contributes to recurring TAMP procedures driven by physician satisfaction and repeat ordering behavior, which management highlighted as a critical indicator of durable adoption. Furthermore, the transition of up to 15 active TIGER-PACT phase 3 trial sites to commercial use represents a near-term, underappreciated catalyst that could accelerate revenue growth in the second half of 2026, as these sites already have familiarity with the device and are motivated by observed clinical benefits, reducing the typical sales cycle and activation lag seen in new center onboarding.
The RenovoCath device benefits from exceptionally high gross margins of 85.1% in Q1 2026, reflecting a capital-efficient business model where the single-use nature of the catheter drives recurring revenue with minimal incremental cost per procedure, and management emphasized that ongoing R&D optimizations are focused on manufacturing streamlining rather than fundamental design changes, meaning that as procedure volumes increase with center expansion, operating leverage will significantly improve cash burn and accelerate the path to profitability without requiring substantial new investment. This structural advantage is reinforced by the company’s $12.4 million cash position as of March 31, 2026, which provides sufficient runway to fund operations into 2027, allowing management to focus purely on revenue generation and commercial scaling rather than fundraising distractions, a rare position for a early-stage medical device company in the interventional oncology space.
Physician advocacy and satisfaction are emerging as powerful, organic drivers of adoption, with clinicians citing the toxicity profile, potential lifespan preservation, and early efficacy signals as key reasons for preferring RenovoCath over systemic chemotherapy, particularly in locally advanced pancreatic cancer, and this real-world validation is being amplified by investigator-initiated trials (IITs) in metastatic and resectable pancreatic cancer at institutions like Moffitt Cancer Center and the University of Vermont, which, while not yet commercialized, are building clinical evidence that could expand the addressable market beyond the current TIGER-PACT indication and create additional demand channels that management did not fully quantify but acknowledged as areas of strong interest.

▼ Bear case

Despite strong quarterly revenue growth, RenovoRx remains deeply unprofitable with Q1 2026 operating expenses of approximately $3.9 million ($1.2 million R&D + $2.7 million SG&A) generating a significant operating loss, and while management attributes SG&A increases to timing differences, the absolute level of spending raises concerns about the scalability of the commercial model, especially given that the company is still in the early stages of center activation and has not yet demonstrated that revenue growth can consistently outpace the fixed costs associated with maintaining a field sales team, clinical support, and regulatory infrastructure across a growing geographic footprint.
The company’s reliance on the TIGER-PACT phase 3 trial for long-term validation and reimbursement expansion creates a material risk, as the trial is not expected to read out until mid-to-late 2027, meaning that near-term commercial success is decoupled from the pivotal clinical data that would be necessary to secure broad payer coverage, and without favorable trial results, the current adoption driven by physician enthusiasm and IITs may not translate into sustainable reimbursement rates or expanded indications, leaving the business vulnerable to a scenario where centers adopt the device experimentally but fail to integrate it into standard of care due to lack of robust clinical evidence.
While management highlights a robust pipeline of 48 total centers (16 active + 32 in evaluation), the conversion rate from evaluation to active status remains unclear, and the historical lag observed in 2025—where it took the full year to grow from 5 to 8 active centers—suggests that the current pipeline may not convert as quickly as implied, particularly if value analysis committees (VACs) at leading institutions require more extensive health economic data or comparative effectiveness studies than currently available, which could slow the anticipated acceleration in center activations and undermine the confidence in achieving 36 active centers by year-end 2026.

Despite strong quarterly revenue growth, RenovoRx remains deeply unprofitable with Q1 2026 operating expenses of approximately $3.9 million ($1.2 million R&D + $2.7 million SG&A) generating a significant operating loss, and while management attributes SG&A increases to timing differences, the absolute level of spending raises concerns about the scalability of the commercial model, especially given that the company is still in the early stages of center activation and has not yet demonstrated that revenue growth can consistently outpace the fixed costs associated with maintaining a field sales team, clinical support, and regulatory infrastructure across a growing geographic footprint.
The company’s reliance on the TIGER-PACT phase 3 trial for long-term validation and reimbursement expansion creates a material risk, as the trial is not expected to read out until mid-to-late 2027, meaning that near-term commercial success is decoupled from the pivotal clinical data that would be necessary to secure broad payer coverage, and without favorable trial results, the current adoption driven by physician enthusiasm and IITs may not translate into sustainable reimbursement rates or expanded indications, leaving the business vulnerable to a scenario where centers adopt the device experimentally but fail to integrate it into standard of care due to lack of robust clinical evidence.
While management highlights a robust pipeline of 48 total centers (16 active + 32 in evaluation), the conversion rate from evaluation to active status remains unclear, and the historical lag observed in 2025—where it took the full year to grow from 5 to 8 active centers—suggests that the current pipeline may not convert as quickly as implied, particularly if value analysis committees (VACs) at leading institutions require more extensive health economic data or comparative effectiveness studies than currently available, which could slow the anticipated acceleration in center activations and undermine the confidence in achieving 36 active centers by year-end 2026.

Segments Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	primary	182.50 Bn	33.64	3.92	32.61 Bn
2	ISRG	Intuitive Surgical Inc	primary	126.92 Bn	40.19	11.50	-
3	MDT	Medtronic plc	primary	117.99 Bn	22.38	3.14	28.15 Bn
4	SYK	Stryker Corp	primary	104.23 Bn	27.95	4.03	14.94 Bn
5	BSX	Boston Scientific Corp	primary	64.98 Bn	17.68	3.10	12.62 Bn
6	EW	Edwards Lifesciences Corp	primary	49.94 Bn	49.76	7.67	0.60 Bn
7	ALC	Alcon Inc	primary	33.03 Bn	51.38	3.07	4.15 Bn
8	DXCM	Dexcom Inc	primary	32.06 Bn	32.07	6.45	-

RenovoRx RNXT

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password